BioPharma DiveOriginal article
Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit
Data ReadoutpositivePositive
AI Analysis
Summary
Arrowhead's experimental RNAi drug demonstrated the ability to cross the blood-brain barrier when administered subcutaneously and reduced levels of a protein associated with Alzheimer's disease, representing a first-in-class achievement for this drug delivery approach.
Clinical Trial Data
Outcome Details
RNAi drug crossed into brain and reduced protein levels implicated in Alzheimer's disease
Importance:6/10
Sentiment:
0.70
RNAiAlzheimer's diseasesubcutaneous administrationprotein reductionCNS penetration
Read the original article
Published by BioPharma Dive on October 14, 2026 3:54 PM